Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 6, 2014, Pages 571-580

  Cao, Yanguang ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Distribution; Minimal PBPK models; Monoclonal antibody; PBPK

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD VESSEL PERMEABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; FEASIBILITY STUDY; HUMAN; INTERSTITIAL FLUID; PLASMA CLEARANCE; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM; BIOLOGICAL MODEL; CAPILLARY PERMEABILITY; COMPUTER SIMULATION; KINETICS; MALE; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CAPILLARY PERMEABILITY; COMPUTER SIMULATION; HUMANS; KINETICS; MALE; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION;

EID: 84911976551     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9374-0     Document Type: Article

References (25)

1. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413–415
2. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341:1192–1198
3. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301–316
4. Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–449
5. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548–558
6. Richter WF, Grimm HP, Theil FP (2011) Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. J Pharmacokinet Pharmacodyn 38:581–593
7. Garzone PD, Atkinson AJ Jr (2012) In search of physiologically based distribution volume estimates for macromolecules. Clin Pharmacol Ther 92:419–421
8. Cao Y, Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39:711–723
9. Cao Y, Balthasar JP, Jusko WJ (2013) Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 40:597–607
10. Sarin H (2010) Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2:14
11. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687–709
12. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67–86
13. Wagshul ME, Johnston M (2013) The brain and the lymphatic system. Immunology of the Lymphatic System. Springer, New York, pp 143–164
14. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095
15. Stucker O, Pons-Himbert C, Laemmel E (2008) Towards a better understanding of lymph circulation. Phlebolymphology. 15:31–36
16. Wiig H, Tenstad O (2001) Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. Am J Physiol Heart Circ Physiol 280:H1505–H1512
17. Wiig H, Kaysen GA, al-Bander HA, De Carlo M, Sibley L, Renkin EM (1994) Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. Am J Physiol 266:H212–H219
18. D’Argenio DZ, Schumitzky A (2009) ADAPT V User’s Guide: Pharmacokinetic/Pharmacodynamic System Analysis Software. Biomedical Simulations Resource, Los Angeles
19. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21:2153–2163
20. Davies PF, Ross R (1978) Mediation of pinocytosis in cultured arterial smooth muscle and endothelial cells by platelet-derived growth factor. J Cell Biol 79:663–671
21. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA (2012) Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 14:554–558
22. Schmidt MM, Wittrup KD (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8:2861–2871
23. Golay J, Semenzato G, Rambaldi A, Foa R, Gaidano G, Gamba E, Pane F, Pinto A, Specchia G, Zaja F, Regazzi M (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5:826–837
24. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12:6517–6522
25. Cao YG and Jusko WJ (2014) Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. doi:10.1007/s10928-014-9372-2